KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Market Cap | $683,720 | $417,528 | $247,392 | $311,542 |
| - Cash | $98,644 | $31,789 | $56,238 | $30,732 |
| + Debt | $6,307 | $7,317 | $8,232 | $8,188 |
| Enterprise Value | $591,383 | $393,056 | $199,386 | $288,998 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$86,167 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$173,326 | -$134,280 | -$94,368 | -$80,746 |
| % Margin | – | – | – | – |
| Net Income | -$183,444 | -$126,644 | -$92,907 | -$82,339 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.69 | -3.44 | -3.33 | -3.36 |
| % Growth | -7.3% | -3.3% | 0.9% | – |
| Operating Cash Flow | -$152,907 | -$89,231 | -$75,261 | -$78,134 |
| Capital Expenditures | -$434 | -$443 | -$1,196 | -$931 |
| Free Cash Flow | -$153,341 | -$89,674 | -$76,457 | -$79,065 |